Clinical Trials Logo

Citation(s)

Phase II Study of Bay 43-9006 (Sorafenib) With Evaluation of RAS Signal Pathway in Patients With Relapsed Non-Small Cell Lung Cancer

Details for clinical trial NCT00098254